Texas Capital Funds Trust Texas Capital Government Money Market ETF (NYSE: MMKT)

Ultime notizie per Texas Capital Funds Trust Texas Capital Government Money Market ETF (NYSE:MMKT)

The Fund seeks to achieve its investment objective by investing at least 80% of its assets in a diversified portfolio of high quality, U.S. government money market instruments, including U.S. government money market instruments subject to repurchase agreements under normal circumstances.

Texas Capital Government Money Market ETF

Texas Capital Funds Trust Texas Capital Government Money Market ETF

Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) will release earnings results for the third quarter, after the <a href="https://www.benzinga.com/quote/arm/earnings">closing bell on Wednesday, May 7.</a>
Analysts expect the Cambridge, the UK-based company to report quarterly earnings at 52 cents per share, up from 36 cents per share in the year-ago period. Arm Holdings projects to report quarterly revenue at $1.23 billion, compared to $928 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 16, Cadence announced plans to acquire Arm Artisan Foundation IP business.
Arm Holdings shares rose 0.4% to close at $122.44 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>UBS analyst Timothy Arcuri maintained a Buy rating and cut the price target from $215 to $165 on April 29, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Barclays analyst Blayne Curtis maintained an Overweight rating and slashed the price target from $155 to $125 on April 22, 2025. This analyst has an accuracy rate of 70%.</li>
<li>B of A Securities analyst Vivek Arya maintained a Buy rating and slashed the price target from $180 to $144 on April 16, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Loop Capital analyst Ananda Baruah maintained a Buy rating and increased the price target from $180 to $195 on Feb. 10, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Raymond James analyst Srini Pajjuri maintained an Outperform rating and boosted the price target from $160 to $175 on Feb. 6, 2025. This analyst has an accuracy rate of 79%.</li>
</ul>
Considering buying ARM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07033801/image-63-1024x592.png" alt="" class="wp-image-904968" style="width:505px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07033801/image-63-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07033801/image-63-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07033801/image-63-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07033801/image-63.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Markets

Analyst Ratings

Trading Ideas

Arm Holdings Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

WIIM

NCEW

NCEW stock has given up its prior gain. New Century Logistics shares were trading higher after signing a memorandum of understanding with Soradynamics to develop and deploy an in-vehicle drone logistics system.

Keybanc analyst Sangita Jain maintains Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) with a Overweight and raises the price target from $67 to $74.

PRIM

Keybanc Maintains Overweight on Primoris Services, Raises Price Target to $74

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>) with a Market Perform and raises the price target from $104 to $106.

Keefe, Bruyette & Woods Maintains Market Perform on Aflac, Raises Price Target to $106

Citigroup analyst Asiya Merchant maintains Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Neutral and lowers the price target from $39 to $37.

SMCI

Citigroup Maintains Neutral on Super Micro Computer, Lowers Price Target to $37

Keybanc analyst Justin Patterson maintains Nerdwallet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRDS#NASDAQ">NRDS</a>) with a Overweight and raises the price target from $14 to $15.

NRDS

Keybanc Maintains Overweight on Nerdwallet, Raises Price Target to $15

Keybanc analyst Sangita Jain maintains KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) with a Overweight and raises the price target from $59 to $63.

Keybanc Maintains Overweight on KBR, Raises Price Target to $63

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is up to nearly $97,000, boosted by renewed liquidity from China and heightened anticipation around the FOMC's interest rate decision. But traders remain split on whether this marks the start of another rally or a setup <a href="https://www.benzinga.com/money/bitcoin-price-prediction">for another correction.</a>
What Happened: Crypto trader CJ <a href="https://x.com/CJ900X/status/1920055822593253603">remains</a> cautious. 
He says Bitcoin must flip the $99,000–$102,000 resistance zone to shift market bias toward new all-time highs and a potential run to $125,000. 
Until then, CJ expects downside toward $92,700, and possibly $85,100, key zones of liquidity.
On shorter timeframes, CJ is watching for short setups above local highs and long entries near or below $92,700. His current strategy emphasizes patience, waiting for cleaner setups instead of chasing noisy, low-quality trades.
A potential trade idea involves tagging a local fair value gap followed by a run of equal highs into the FOMC.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/05/45191302/corporations-will-pour-330-billion-into-bitcoin-by-2029-bernstein">Corporations Will Pour $330 Billion Into Bitcoin By 2029: Bernstein</a>
Why It Matters: Analyst Stockmoney Lizards <a href="https://x.com/StockmoneyL/status/1920008007909323143">adds</a> that Bitcoin's movement isn't solely dictated by FOMC decisions or rate hikes.
Instead, it follows broader market cycles driven by macro forces and investor psychology.
Looking at the macro chart, they see a clear pattern: a post-COVID boom, the 2022 bear market bottom near the 200-week simple moving average, a 2024 breakout to new highs and a potential 2025 consolidation phase after crossing $100,000.
Macroeconomic events often coincide with moments of extreme fear or euphoria, reinforcing historical market patterns. 
Even if Bitcoin sees an extended correction now, the outlook for 2025 remains bullish. 
The trader emphasizes tuning out short-term noise and staying focused on the longer cycle.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45192498/bitcoins-key-level-is-96500-analyst-warns-but-heres-what-could-trigger-a-breakdown">Bitcoin&#8217;s Key Level Is $96,500, Analyst Warns, But Here&#8217;s What Could Trigger A Breakdown</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Hovers Around $97,000, But A Correction May Be Around The Corner, Traders Warn

IBM's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) stock is strutting like it owns the runway. Up 48% in the past year and 13% just this year, the legacy tech giant is flexing serious momentum and the charts are confirming it.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0507"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07082641/Screenshot-2025-05-07-at-5.56.20-PM.png" alt="" class="wp-image-905522" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07082641/Screenshot-2025-05-07-at-5.56.20-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07082641/Screenshot-2025-05-07-at-5.56.20-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0507">Chart created using Benzinga Pro</a>
Trading at $249.12, IBM stock sits comfortably above its five, 20 and 50-day moving averages, with a bullish MACD (moving average convergence/divergence) and RSI (relative strength index) suggesting there's still gas in the tank. Technical traders call it &#8216;strongly bullish.&#8217; Bulls call it a &#8220;no-brainer."
But IBM isn't just riding the AI wave &#8211; it's building the surfboard. At the IBM Think conference in Boston, analysts came away impressed with the company's laser-focused AI and hybrid cloud strategy. 
Read Also: <a href="https://www.benzinga.com/25/05/45218573/ibms-ai-watsonx-integrates-with-oracle-cloud-to-boost-enterprise-productivity">IBM AI Watsonx Integrates With Oracle Cloud To Boost Enterprise Productivity</a>
<h2 class="wp-block-heading">Why Dan Ives Is &#8216;Incrementally More Bullish&#8217; On IBM</h2>
Wedbush's Dan Ives is going full throttle, reiterating an Outperform rating and setting a $300 price target. He left the event "incrementally more bullish," noting IBM's sprawling AI use cases, including 70+ AI-infused workflows and over $5B already tied to its generative AI business.
The Z17 mainframe is back in the spotlight, Watsonx Orchestrate lets users build AI agents in minutes, and management is even cozying up with Meta to potentially integrate into the Llama LLM stack. As Ives puts it, IBM's stack is "built for the enterprise AI revolution."
<h2 class="wp-block-heading">JPMorgan Says IBM Is Leading By Example</h2>
JPMorgan's Brian Essex is more measured, holding a Neutral rating, but even he admits IBM is leading by example. He highlighted IBM's internal AI efforts, which have saved $3.5 billion, automating everything from HR to financial forecasting, and proving it&#8217;s not just selling AI—it's living it.
With HashiCorp integration unlocking hybrid automation and a bet on small models paying off, IBM seems determined to reinvent enterprise tech one AI agent at a time.
IBM isn't your grandfather's tech stock anymore. It's leaner, smarter and increasingly essential in the AI-powered future of enterprise.
Don't be surprised if $300 is just the next pit stop.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45251508/warren-buffett-falls-behind-nancy-pelosi-in-stock-market-returns-over-the-last-11-years-heres-what-data-shows">Warren Buffett Falls Behind Nancy Pelosi In Stock Market Returns Over The Last 11 Years: Here&#8217;s What Data Shows</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Technicals

Tech

IBM Thinks Big, AI Delivers Bigger – Why Bulls Are Charging Toward $300

Keybanc analyst Todd Thomas maintains Getty Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTY#NYSE">GTY</a>) with a Overweight and lowers the price target from $35 to $33.

Keybanc Maintains Overweight on Getty Realty, Lowers Price Target to $33

BWS Financial analyst Hamed Khorsand maintains Interparfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) with a Buy and maintains $172 price target.

IPAR

BWS Financial Maintains Buy on Interparfums, Maintains $172 Price Target

HGTY

Hagerty shares are trading higher after the company reported better-than-expected Q1 financial results.

Keybanc analyst Alex Markgraff maintains Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) with a Overweight and raises the price target from $80 to $90.

Keybanc Maintains Overweight on Global Payments, Raises Price Target to $90

RCUS

Arcus Biosciences shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, Wells Fargo lowered its price target on the stock from $29 to $26.

PARR

Par Pacific Holdings shares are trading higher after the company reported better-than-expected Q1 sales results.

GEO Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) shares are trading lower after the company reported first-quarter revenue of $604.6 million, which missed <a href="https://www.benzinga.com/pressreleases/25/05/b45246791/the-geo-group-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">the consensus of $611.81 million</a>.
<ul>
<li>Adjusted EBITDA declined to&nbsp;$99.8 million&nbsp;from&nbsp;$117.6 million&nbsp;a year ago quarter.</li>
<li>Adjusted EPS&nbsp;of&nbsp;14 cents came below&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;18 cents</a>.</li>
<li>The results reflect a general and administrative expense increase of around $5 million.</li>
<li>At the end of the first quarter, net debt totaled approximately $1.68 billion, with around $65 million in cash and cash equivalents.</li>
</ul>
George C. Zoley, Executive Chairman of GEO, said, &#8220;During the first quarter of 2025, we announced two important contract awards for the reactivation of two company-owned facilities totaling 2,800 beds and representing in excess of $130 million in annualized revenues.&#8221;
&#8221;We have taken several important steps to be prepared to meet that opportunity, including making a significant investment commitment of $70 million to strengthen our capabilities to deliver expanded detention capacity, secure transportation, and electronic monitoring services to ICE and the federal government. We also recently completed a reorganization of our senior management team to oversee the operational execution of this expected future growth activity.&#8221;
Outlook: Geo raised FY25 outlook for EPS to 77 cents to 89 cents from 74 cents to 88 cents (vs. the consensus estimate of $1.22) and revenue to around $2.53 billion from $2.50 billion <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">(vs. consensus of $2.66 billion)</a>.
For the second quarter, the company expects second quarter GAAP EPS of 15 cents to 17 cents vs. the street view of 24 cents and sales of $615 million—$625 million vs. the consensus of $635.62 million.
In 2025, the company expects to further reduce the total net debt by around&nbsp;$150 million&nbsp;to&nbsp;$175 million, bringing the total net debt to about&nbsp;$1.54 billion.
For 2025, the company projects capital expenditures of $120 million-$135 million.
&#8220;The first half of the year is expected to be impacted by higher overhead and operating expenses as well as increased capital expenditures to position our company for future growth, which is expected to begin to layer in during the second half of 2025 and normalize in 2026.&#8221;, added Zoley.
Investors can gain exposure to the stock via&nbsp;Ballast Small/Mid Cap ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGMT#NYSE">MGMT</a>) and&nbsp;Innovator IBD Breakout Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOUT#NYSE">BOUT</a>).
Price Action: GEO shares are down 3.16% at $30.37 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take" target="_blank" rel="noreferrer noopener">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a></li>
</ul>
Image: Shutterstock

Equities

Mid Cap

Guidance

Movers

BOUT

MGMT

GEO Missed Q1 Targets On Rising Costs And Debt, Guides Q2 Below Street Estimates

Keybanc analyst Jeffrey Hammond maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Overweight and raises the price target from $71 to $76.

Keybanc Maintains Overweight on Celanese, Raises Price Target to $76

Barrington Research analyst Vincent Colicchio maintains Hackett Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) with a Outperform and lowers the price target from $36 to $32.

HCKT

Barrington Research Maintains Outperform on Hackett Group, Lowers Price Target to $32

IMPORTANT SAFETY INFORMATION ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).
The most common adverse reactions (≥1%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).
The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Biotech

General

ARQT

Arcutis Biotherapeutics Says ZORYVE Foam 0.3% Linked To Adverse Reactions Including Headache, Nausea, And Diarrhea, With Flammability Risk And Contraindications For Liver-Impaired Patients Highlighted In Safety Profile Under FDA Review

RVLV

Revolve Group shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, Raymond James and UBS lowered their respective price targets on the stock.

Comments

Texas Capital Funds Trust Texas Capital Government Money Market ETF

Notizie

Ultime notizie per Texas Capital Funds Trust Texas Capital Government Money Market ETF (NYSE:MMKT)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO